INTRODUCTION
AMPK (AMP-activated protein kinase) plays a critical role in cellular responses to low energy levels by switching off pathways that consume energy and switching on those that produce it [1] . AMPK is known to be activated under conditions that deplete cellular ATP and elevate AMP levels, such as glucose deprivation, hypoxia, ischaemia and heat shock [2] [3] [4] . Previous work, however, indicates that other mechanisms, independent of bioenergetic changes, might be involved in AMPK activation; these include CaMKKII (Ca 2+ /calmodulin kinase kinase II) [5, 6] and signalling by ROS (reactive oxygen species) [7, 8] . Thus AMPK might be playing roles other than the regulation of cellular energy metabolism.
AMPK is a heterotrimeric protein, comprising two catalytic (α1 and α2) and five different regulatory (β1-2 and γ 1-3) subunits, and functions as a protein serine/threonine kinase. The enzyme is expressed ubiquitously, but the distribution of the two catalytic subunits is not uniform. Although the α2 subunit is mainly located in tissues with high energy demand (muscle, brain and liver), the α1 subunit seems to be more widespread and accounts for the majority of the activity in tissues such as the pancreas, leucocytes, smooth muscle and endothelial cells, including tissues where the α2 subunit is located [9, 10] . Although differences between the two subunits have been suggested, their differential roles have not been clearly established [9, 11] .
We have previously shown that when human vascular endothelial cells [HUVECs (human umbilical-vein endothelial cells)] are exposed to a low concentration of O 2 (i.e. 3 %), AMPKα1 is activated by a mechanism independent of energy changes, but dependent on mtROS (mitochondrial ROS) generated in response to the interaction of NO with the cytochrome c oxidase [8, 12] . This led us to hypothesize that activation of AMPK by mtROS may be involved in cellular defence. In the present study we show evidence indicating a novel role for AMPKα1 in the control of a response that preserves the highly antioxidant status of endothelial cells.
EXPERIMENTAL

Cells and reagents
HUVECs were purchased from PromoCell. Control mockinfected and AMPKα1-silenced HUVECs were grown until passage 3-5 in EGM (endothelial cell growth medium)-2 (PromoCell) or alternatively in EGM-2 RPF (red phenol free) at 37
• C in a 5% CO 2 /humidified air incubator. All experimental procedures were carried out when the cells were 80 % confluent. A low O 2 concentration was achieved by incubation of the cells at 3 % O 2 at 37
• C in an O 2 -controlled hypoxic chamber (Coy Laboratory Products) for the times indicated. Anti-phospho-AMPKα1-Thr 172 and anti-phospho-ACC (acetyl-CoA carboxylase) antibodies were from Cell Signaling Technologies and were used as indicated by the supplier. Foxo3a (forkhead transcription factor 3a) antibodies, anti-eNOS [endothelial NOS (NO synthase)] antibodies, MnSOD
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(manganese superoxide dismutase), γ GCS (γ -glutamylcysteine synthase) and α-tubulin were obtained from Santa Cruz Biotechnology. Caspase Glow 3/7 was purchased from Promega and the BrdU (bromodeoxyuridine)-proliferation kit was from Roche.
Lentiviral infection
The pFIV U6/H1 lentiviral system (System Biosystems) was used to deliver RNAi (RNA interference) sequences against human AMPKα1 (HUGO gene nomenclature PRKAA1; GenBank ® accession number NM_006251). Five different sequences were selected and three of these produced a greater than 80 % reduction in the expression of the protein, as assessed by Western blotting. Control cells were infected with a scrambled sequence (see Supplementary Table S1 at http://www. BiochemJ.org/bj/421/bj4210163add.htm for details of sequences used). Briefly, HUVECs were infected with 0.45 μm filtered conditioned medium from co-transfected HEK (human embryonic kidney)-293T cells with packaging plasmids (System Biosciences) and the respective pFIV, in the presence of 4 μg of polybrene (hexadimethrine bromide; Sigma) and 2 μg of Reagent Plus (Invitrogen). Two successive rounds of infection were performed at 24 h intervals and the infected cells were selected for their resistance to puromycin (1 μg/ml) for 3 days.
Q RT-PCR (quantitative reverse transcription-PCR)
Total RNA was isolated using Tri-Reagent following the manufacturer's protocol (Sigma). First-strand cDNA was synthesized with a SuperScript First-Strand Synthesis System for RT-PCR using SuperScript II reverse transcriptase (Invitrogen). Control PCR reactions were also carried out on total RNA that had not been reverse-transcribed to test for the presence of genomic contamination. Q RT-PCR reactions were carried out using SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich) in triplicate (ABI Prism 7700 sequencer; Applied Biosystems). Gene-specific primers were designed by Primer Express 2.0 (Applied Biosystems) and then subjected to BLAST analysis to ensure the primer specificity (see Supplementary Table S1 for sequences used). Relative quantification was achieved by normalization to endogenous β-actin. The specificity of the products of the Q RT-PCR was verified by PCR melting curves and/or 2 % (w/v) agarose gels.
Western blot analysis
HUVECs were grown for 1 week, with a change of medium every 2 days. On the day of the experiment, fresh medium was added and treatments were performed as indicated. Cells were washed with PBS, scraped off in ice-cold PhosphoSafe buffer (Novagen), and centrifuged for 10 min at 13 000 g at 4 • C. From clear supernatants, the protein concentration was determined using the Dc kit (Bio-Rad) using BSA as a control. Sample aliquots were boiled for 2 min and equal amounts (usually 20 μg) of total protein were electrophoresed in pre-cast SDS/PAGE 4-15 % gradient gels (Bio-Rad). Proteins were transferred on to nitrocellulose membranes (Pharmacia), assessed for equal loading/transference by Red Ponceau tinction, and immunoblotted overnight with the primary antibodies indicated (typically 1:1000 dilution), followed by secondary antibody conjugated with horseradish peroxidase (1:2000 dilution). The ECL Plus TM Western blotting detection kit (GE Healthcare) was used for detection. Western blots shown in the Figures of the present paper are representative of at least three independent experiments.
Production of intracellular ROS
Control or AMPKα1-silenced HUVECs were seeded (20 000 cells/well) and grown in 24-well plates with RPF EGM-2 medium. On the day of the experiment, the medium was changed and the cells were incubated with 20 μM CM-DCF-DA [5-and 6-)-chloromethyl-2 ,7 -dichlorodihydrofluorescein diacetate acetyl ester] dissolved in ethanol for 30 min. Cells were washed (three times) with medium and subjected to various treatments for 4 h. The cells were then lysed and centrifuged to remove debris, and the CM-DCF-DA-associated ROS fluorescence generated during the 4 h treatment was measured using a thermostatically controlled multiwell plate reader fluorimeter (excitation 495 nm, emission 520 nm, Victor2; PerkinElmer). Data (corrected to negative controls) were represented graphically.
Measurement of apoptosis and cell proliferation
Control or AMPKα1-silenced HUVECs were seeded (20 000 cells/well) and grown in white-walled 96-well plates with RPF EGM-2 medium. On the day of the experiment, the medium was renewed immediately prior to the studies. The culture flasks were placed in a humidified O 2 -controlled hypoxic chamber (Coy Laboratory Products). To obtain a low O 2 concentration, the air in the chamber was completely replaced by a gas mixture containing 5 % CO 2 and 95 % N 2 . The O 2 pressure (pO 2 ) in the incubator was set at 3 % (v/v). The cells were incubated in the chamber for 4 h with tBHP (tert-butylhydroperoxide; 50 μM) at 37
• C. Then, the apoptosis ratio of the cells was assessed with the CaspaseGlow 3/7 kit (Promega) following the manufacturer's protocol and measured using a thermostatically controlled multiwell plate reader luminometer (Victor2; PerkinElmer). For proliferation studies, control or AMPKα1-silenced HUVECs were seeded on to a 96-well plate (20 000 cells/well), incubated with BrdU for 4 h at 3 % O 2 , washed three times with fresh medium, and then treated as indicated in the manufacturer's protocol (Roche). The product of the ELISA reaction was monitored on a 96-multiwell plate spectrophotometer (Spectramax Plux; Molecular Diagnostics) and values (corrected to negative controls) were represented graphically.
Statistical analysis
To compare data obtained under different conditions an ANOVA test was used. Differences were evaluated using a Student's t test. Values stated are means + − S.E.M. Results were considered to be significantly different when P < 0.05.
RESULTS
Effect of silencing AMPKα1 on the expression of antioxidant genes
HUVECs express mainly the AMPK α1, β1 and γ 1 subunits, with very little expression of the catalytic subunit α2 at atmospheric (21 %) or at 3% O 2 ( Figure 1A ). We used reverse genetics against AMPKα1 to study its functions in these cells. Using an RNAi lentiviral system (see Supplementary Table S1 for details of sequences) we silenced the catalytic AMPKα1, both at the mRNA and protein levels (approx. 80 % reduction; Figures 1B  and 1C respectively) . We confirmed the functional silencing of AMPKα1 by analysing the phosphorylation status of ACC, a known downstream target of AMPKα1. A marked reduction in the post-transcriptional inhibition of ACC was observed in AMPKα1-silenced cells (adapted to 3 % O 2 ) when compared with control (mock-transfected) cells ( Figure 1D ). We also tested the activation of AMPKα1 by evaluating the phosphorylation state of The protein levels of AMPKα1 were assayed by Western blotting at 3 % O 2 using a pan AMPKα antibody. Cells infected with a scrambled sequence were used as a control. α-Tubulin was used as an internal loading control. The detected protein was quantified by densitometry from three independent experiments. (D) Validation of AMPKα1-silencing in HUVECs. The phosphorylation of ACC at 3 % O 2 was assessed by immunoblotting. α-Tubulin was used as an internal loading control. The detected protein was quantified by densitometry from three independent experiments. (E) Effect of the O 2 concentration on AMPK activation in HUVECs. Control and AMPKα1-silenced cells were incubated for 4 h at 21 % and 3 % O 2 in a hypoxic chamber and AMPK activation (evaluated as phosphorylated AMPK) was assessed by Western blotting. α-Tubulin was used as an internal loading control. The detected protein was quantified by densitometry from three independent experiments. *P < 0.05, significant difference from control value. Ctrl, control; iRNA, RNAi; p, phosphorylated.
the protein. In control HUVECs, there was little phosphorylation of AMPKα1 at 21% O 2 , but greater phosphorylation at 3 % O 2 , which is the concentration that produced maximum activation of AMPKα1 in these cells [8] (Figure 1E ). In contrast, AMPKα1 was not phosphorylated in the silenced cells at 3 % O 2 , indicating the absence of both AMPKα1 and of any compensatory activity from the α2 catalytic subunit in these cells.
We then measured changes in the content of mRNA of antioxidant genes in control and AMPKα1-silenced HUVECs at 3 % O 2 . Our results showed a marked reduction in the expression of MnSOD, catalase, γ GCS and thioredoxin (Figure 2A ). Immunoblot analysis confirmed that these changes also occurred at the protein level ( Figure 2B ). Interestingly, other genes which have been reported to be part of the cellular antioxidant defence in different conditions [e.g. GSTP1 (glutathione transferase P 1), ALDHA1 (aldehyde dehydrogenase 1) and HO1 (haem oxygenase 1)] were unaffected by silencing AMPKα1 (Figure 2A ).
Transcription factors involved in the downstream signalling of AMPKα1
We monitored changes in expression of several putative downstream transcription factors of AMPKα1 and found a significant reduction in PGC1α (peroxisome-proliferator-activated receptor γ co-activator 1α) mRNA and protein in the AMPKα1-silenced cells at 3 % O 2 ( Figures 3A and 3B respectively) . We also found a significant reduction in the expression of Foxo3a, another transcription factor associated with the expression of Western blot analysis showed a reduction in the expression of these proteins at 3 % O 2 in AMPKα1-silenced cells when compared with the control cells. α-Tubulin was used as an internal loading control. The detected protein was quantified by densitometry from three independent experiments. *P < 0.05, significant difference from control value. CAT, catalase; Ctrl, control; iRNA, RNAi.
antioxidant genes ( Figures 3A and 3C) . However, the expression of Nrf2 (nuclear factor-erythroid 2-related factor 2) or NF-κB (nuclear factor κB), transcription factors that have been implicated in the oxidative stress response, remained unchanged in the AMPKα1-silenced cells ( Figure 3A) . Since phosphorylated CREB (cAMP-response-element-binding protein) has been found to be a physiological regulator of PGC1α expression [13, 14] , we used antibodies raised against phospho-CREB and showed by immunoblotting that there was a reduction in the phosphorylation of CREB in the AMPKα1-silenced cells ( Figure 3B ).
Effect of silencing AMPKα1 on the mitochondrial content and the generation of ROS
We measured the expression of the mitochondrial-encoded proteins CcOx1 (cytochrome c oxidase subunit 1) and ATPase6 (ATPase subunit 6) and found that the mRNA of both genes was reduced by approx. 50 % in AMPKα1-silenced cells at 3 % O 2 ( Figure 4A ). This indicated a reduction in mitochondrial content in these cells, consistent with the observed reduction in PGC1α, which is a key transcription factor controlling the biogenesis of mitochondria [15] . We then used CM-DCF-DA to monitor the amount of ROS in the cells following various treatments and found that there was an increase in CM-DCF-DA fluorescence in control cells incubated for 4 h at 3 % O 2 compared with those incubated at 21 % O 2 . This increase in ROS at 3 % O 2 was greatly enhanced in AMPKα1-silenced cells ( Figure 4B) . Treatment with the NOS inhibitor L-NMMA (N G -monomethyl-L-arginine; 1 mM) abolished the increase in ROS in control cells at 3 % O 2 , and partially reduced the amount of ROS in silenced cells at 3 % O 2 . In contrast, treatment of the cells with the antioxidant NAC (Nacetyl cysteine; 10 mM) abolished the increase in ROS at 3 % O 2 in both control and silenced cells ( Figure 4B ).
Sensitivity of AMPKα1-silenced HUVECs to oxidative stress
To test whether the silencing of AMPKα1 produced an increased sensitivity of the cells to oxidative stress, we exposed transfected and control cells to the pro-oxidant agent tBHP at 3 % O 2 . There was no significant increase in apoptosis in the AMPKα1-silenced cells compared with the control cells ( Figure 5A ). Exposure to tBHP (50 μM) increased apoptosis in both cell types, but the increase was significantly greater in the transfected cells ( Figure 5A ). We also monitored the in vitro cell proliferation of these cells at 3 % O 2 using BrdU incorporation and found a marked reduction in DNA synthesis in AMPKα1-silenced cells, indicating a lower rate of metabolic activity and cell proliferation ( Figure 5B ).
Effect of AMPKα1-silencing on the expression of eNOS
We assessed the expression of eNOS in control and transfected cells at 3 % O 2 and found that both mRNA and protein levels of eNOS were dramatically reduced in AMPKα1-silenced cells ( Figures 6A and 6B ).
DISCUSSION
AMPK has been shown to be activated by different stimuli, some of which are independent of changes in AMP levels. Such activators include hypoxic stress [3] , peroxynitrite [16] , adiponectin [17] , leptin [18] , metformin [19] and CaMKKII [5, 6] . We have recently shown that AMPK in HUVECs is activated by NO-dependent mtROS at a low concentration of O 2 (i.e. 3 % O 2 ). This activation can be abolished by reducing mitochondrial DNA (ρ 0 cells) or by the use of antioxidants, and is independent of bioenergetic changes [8] .
In the present study we show that HUVECs express almost exclusively the catalytic α1, and the regulatory β1 and γ 1, subunits of AMPK, in agreement with previous results [20, 21] . We have used RNAi technology by lentiviral transformation to knockout AMPKα1 in these cells by more than 80 %, both at the mRNA and protein level, as well as functionally. Our results clearly indicate that there is no compensatory expression of the α2 subunit in these cells.
We observed that in HUVECs lacking a functional catalytic AMPKα1 subunit, the expression of key components in the antioxidant defence programme was attenuated. Our results show a marked reduction (50-80 %) in mRNA and protein levels of MnSOD, CAT, γ GCS and thioredoxin. Interestingly, other genes Immunoblots showed a significant reduction of Foxo3a both at the expression and protein levels in AMPKα1-silenced cells. α-Tubulin was used as an internal loading control. The detected protein was quantified by densitometry from three independent experiments. *P < 0.05, significant difference from control value. Ctrl, control; iRNA, RNAi.
which have been implicated in the response to oxidative stress (e.g. HO1, GSTP1 and ALDH1A) remained unchanged in the transfected cells. We characterized the molecular components involved in AMPKα1 signalling and found that the expression and protein content of PGC1α (a major regulator of mitochondrial biogenesis and respiration) was significantly reduced in the silenced cells. The expression of PGC1α has previously been demonstrated to be under the control of the transcription factor CREB [22] , the activity of which is determined by its phosphorylation status [23] . We observed a clear reduction in the phosphorylation of CREB in the silenced cells, indicating the involvement of AMPKα1 as an upstream regulator of CREB activity. Indeed, CREB has recently been shown to be a direct target of AMPK [24] .
The FOXO family of transcription factors has been implicated in the regulation of antioxidant genes, in particular in the expression of MnSOD and catalase [25] . We observed that Foxo3a (but not Foxo1a) was significantly reduced in AMPKα1-silenced cells both at the protein and mRNA level, suggesting its involvement in the regulation of the antioxidant defence genes in HUVECs. Foxo3a has recently been reported to be a direct target of AMPKα1, which promotes its activity by phosphorylation [26, 27] . Moreover, caloric restriction mediates an increase in life span in Caenorhabditis elegans by an AMPKα1-and Foxodependent mechanism [26] .
We did not observe changes in expression of Nrf2 or NF-κB in AMPKα1-silenced cells, suggesting that they are not involved in the observed down-regulation of γ GCS and thioredoxin. In the present study, the expression of other known reported downstream effectors of Nrf2 (i.e. GSTP1, ALDHA1 and HO1) also remained unmodified in the transfected cells. Down-regulation of γ GCS, a key enzyme in the synthesis of glutathione, was one of the most significant changes observed in AMPKα1-silenced cells. It has been demonstrated that silencing γ GCS in neuronal cells results in an increase in apoptosis, indicating an important role in neuroprotection [28] . We observed a reduction in the rate of BrdU incorporation into DNA (a marker of cell proliferation and metabolic status) in AMPKα1-silenced cells. Furthermore, there was an increase in apoptosis when these cells were exposed to an external oxidative stressor (tBHP). These results are consistent with the observed reduction of the components of the antioxidant defence system. Silencing AMPKα1 also resulted in a reduction in the expression of two proteins encoded by the mitochondrial DNA, namely CcOx1 and ATPase6. This indicates that the number of mitochondria is reduced, and correlates with the observed decrease in PGC1α in these cells. We also found a reduction in the expression of eNOS at 3 % O 2 , both at the mRNA and the protein level, in AMPKα1-silenced cells. Interestingly, Niwano et al. [29] have previously shown that phospho-CREB up-regulates eNOS expression, which is in accordance with our results.
Greater amounts of ROS were detected at 3 % O 2 than at 21 %, in agreement with previously published results [8] ; this increase was greater in AMPKα1-silenced cells. Treatment with L-NMMA abolished the increase in ROS observed in control cells at 3 % O 2 , but only partially reduced that observed in AMPKα1-silenced cells. Treatment with NAC, however, abolished the enhanced production of ROS at 3 % O 2 in both cell types. We have argued that ROS are generated for signalling purposes by the mitochondria as a result of interaction of NO with cytochrome c oxidase [8, 12] . However, in the AMPKα1-silenced cells the amount of ROS detected was increased despite the fact that ; n = 3. *P < 0.05, significant difference from control value. (B) Effect of AMPKα1-silencing on ROS production. AMPKα1-silenced and control endothelial cells were incubated as described in the Experimental section. The CM-DCF-DA-associated ROS fluorescence was determined using a Victor2 multiwell reader fluorimeter. Values are normalized means + − S.E.M.; n = 3. *P < 0.05, significant difference from respective control value at 21 % O 2 ; §P < 0.05, significant difference from respective non-drug-treated value at 3 % O 2 . Ctrl, control; iRNA, RNAi. (A) The relative expression of eNOS mRNA in the AMPKα1-silenced HUVECs at 3 % O 2 was assessed by Q RT-PCR and the expression was normalized against β-actin and represented as a percentage of the control values. *P < 0.05, significant difference from control value. (B) eNOS protein levels at 3 % O 2 in control and AMPKα1-silenced HUVECs were assessed by Western blotting. α-Tubulin was used as an internal loading control. The detected protein was quantified by densitometry from three independent experiments. *P < 0.05, significant difference from control value. Ctrl, control; iRNA, RNAi.
eNOS and mitochondrial content were reduced. This could be attributable to a decreased inactivation of ROS, due to the fact that antioxidant defence is impaired in these cells, as well as to the activation of other ROS-generating systems that are not sensitive to L-NMMA. There are several reports in the literature that decreasing antioxidant defence results in an increase in detection of mtROS [30, 31] . The origin of these radicals, as well as the transduction of the signal from mtROS to the activated AMPKα1, needs to be established. It is possible that CaMKKII may be an upstream kinase for the activation of AMPKα1 in endothelial cells. Indeed, our preliminary results using STO-609, an inhibitor of CaMKKII, suggest that the activation of AMPKα1 at 3 % O 2 is mediated by CaMKKII.
In summary, the findings of the present study indicate that in vascular endothelial cells AMPKα1 is a key component in a signalling pathway that is initiated by the interaction of NO and mitochondria at physiological O 2 concentrations, and is propagated by the recruitment of several downstream transcription factors and co-activators in order to preserve the cellular antioxidant defences. Considering that this signalling mechanism operates at O 2 concentrations similar to physiological ones, it is tempting to suggest that this signalling pathway, involving NO, mitochondria and AMPKα1 could be part of a homoeostatic system to preserve the highly resistant phenotype of vascular cells. Future work will need to address several questions, including those related to the molecular mechanisms involved in the transduction of the mtROS signal and whether this phenomenon is restricted to the vasculature. The pharmacological activation of AMPKα1 could be beneficial in those diseases mediated by oxidative stress, by improving the endogenous antioxidant defence of the cell.
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